<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-14T03:50:09Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:2445/195230" metadataPrefix="oai_dc">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:2445/195230</identifier><datestamp>2025-12-04T19:10:46Z</datestamp><setSpec>com_2072_1057</setSpec><setSpec>col_2072_478858</setSpec><setSpec>col_2072_478917</setSpec><setSpec>col_2072_478921</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
   <dc:title>Cirrhosis Hampers Early and Rapid Normalization of Natural Killer Cell Phenotype and Function in Hepatitis C Patients Undergoing Interferon-Free Therapy</dc:title>
   <dc:creator>Perpiñán, Elena</dc:creator>
   <dc:creator>Pérez-Del-Pulgar, Sofía</dc:creator>
   <dc:creator>Londoño, María Carlota</dc:creator>
   <dc:creator>Mariño Méndez, Zoe</dc:creator>
   <dc:creator>Bartrés, Concepció</dc:creator>
   <dc:creator>González, Patricia</dc:creator>
   <dc:creator>García-López, Mireia</dc:creator>
   <dc:creator>Pose Méndez, Elisa</dc:creator>
   <dc:creator>Lens García, Sabela</dc:creator>
   <dc:creator>Maini, Mala K</dc:creator>
   <dc:creator>Forns, Xavier</dc:creator>
   <dc:creator>Koutsoudakis, George</dc:creator>
   <dc:subject>Virus de l'hepatitis C</dc:subject>
   <dc:subject>Cirrosi hepàtica</dc:subject>
   <dc:subject>Interferó</dc:subject>
   <dc:subject>Citometria de fluxe</dc:subject>
   <dc:subject>Hepatitis C virus</dc:subject>
   <dc:subject>Hepatic cirrhosis</dc:subject>
   <dc:subject>Interferon</dc:subject>
   <dc:subject>Flow cytometry</dc:subject>
   <dc:description>Background: Chronic hepatitis C virus (HCV) infection impairs natural killer (NK) cell phenotype and function. Whether restoration of NK cells occurs after successful interferon (IFN)-free therapies remains a controversial issue. Aim: To analyze how HCV-related liver cirrhosis impacts changes in NK cells prior and post-IFN-free therapies. Methods: NK cell analysis by multicolor flow cytometry was performed in HCV-infected patients with (n = 17) and without (n = 14) cirrhosis at baseline, week 4 during therapy, and weeks 12 and 48 after the end of therapy (FU12 and FU48, respectively). Non-HCV cirrhotic patients (n = 12) and healthy individuals (n = 12) served as controls. Results: At baseline, HCV cirrhotic patients presented an altered distribution of NK subsets (CD56dim and CD56bright) with higher expression of NKp46, HLA-DR, NKp30, KIR2DL2/L3, NKG2A, and CD85j receptors compared to healthy controls. All frequencies normalized by FU48, except for CD85j+ cells. Likewise, substantial alterations were detected in NK cell function assessed by (i) signal transducer and activator of transcription 1 (STAT1) and phosphorylated levels of STAT1 and STAT4, (ii) degranulation (CD107a), (iii) cytotoxicity [tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)], and (iv) cytokine production [IFN-γ and tumor necrosis factor-α (TNF-α)]. Of note, NK cell function at FU48 remained partially impaired. In contrast, non-cirrhotics showed normal baseline frequencies of HLA-DR-, NKG2A-, and CD85j-expressing NK cells. Importantly, altered baseline frequencies of NK cell subsets and NKp46+ CD56dim cells, as well as NK cell function, were rapidly and completely restored. Conclusions: NK cell phenotype alterations persist after HCV eradication in cirrhotic patients, while their function is only partially restored, compromising immune restoration and immunosurveillance</dc:description>
   <dc:date>2023-03-14T14:12:35Z</dc:date>
   <dc:date>2023-03-14T14:12:35Z</dc:date>
   <dc:date>2020-02-25</dc:date>
   <dc:date>2023-03-14T14:12:35Z</dc:date>
   <dc:type>info:eu-repo/semantics/article</dc:type>
   <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
   <dc:identifier>1664-3224</dc:identifier>
   <dc:identifier>https://hdl.handle.net/2445/195230</dc:identifier>
   <dc:identifier>712017</dc:identifier>
   <dc:identifier>32161581</dc:identifier>
   <dc:language>eng</dc:language>
   <dc:relation>Reproducció del document publicat a: https://doi.org/10.3389/fimmu.2020.00129</dc:relation>
   <dc:relation>Frontiers in Immunology, 2020, vol. 11, p. 129</dc:relation>
   <dc:relation>https://doi.org/10.3389/fimmu.2020.00129</dc:relation>
   <dc:rights>cc-by (c) Perpiñán, Elena et al., 2020</dc:rights>
   <dc:rights>https://creativecommons.org/licenses/by/4.0/</dc:rights>
   <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
   <dc:format>15 p.</dc:format>
   <dc:format>application/pdf</dc:format>
   <dc:publisher>Frontiers Media</dc:publisher>
   <dc:source>Articles publicats en revistes (Medicina)</dc:source>
</oai_dc:dc></metadata></record></GetRecord></OAI-PMH>